Phase 1 CD-19 specific third generation CAR T cell study data supports use of BioOra’s automated manufacture for phase 2
BioOra’s automated CAR T cell platform will be used in an upcoming Phase 2 efficacy trial. SAN DIEGO, CALIFORNIA, UNITED STATES, December 11, 2023 /EINPresswire.com/ -- Results from 25 patients with relapsed or refractory B-cell non-Hodgkin lymphomas on …